Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Nicolas Salvadori; Bo Fan; Waralee Teeyasoontranon; Nicole Ngo-Giang-Huong; Siriluk Phanomcheong; Anita Luvira; Achara Puangsombat; Arunrat Suwannarat; Ussanee Srirompotong; Chaiwat Putiyanun; Tim R Cressey; Luc Decker; Woottichai Khamduang; Linda Harrison; Camlin Tierney; John A Shepherd; Athena P Kourtis; Marc Bulterys; George K Siberry; Gonzague Jourdain

doi:10.1093/cid/ciy982

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Clin Infect Dis. 2019 Jun 18;69(1):144-146. doi: 10.1093/cid/ciy982.

Authors

Nicolas Salvadori^{1

2}, Bo Fan³, Waralee Teeyasoontranon⁴, Nicole Ngo-Giang-Huong^{1

2

5}, Siriluk Phanomcheong⁶, Anita Luvira⁷, Achara Puangsombat⁸, Arunrat Suwannarat⁹, Ussanee Srirompotong¹⁰, Chaiwat Putiyanun¹¹, Tim R Cressey^{1

2

5

12}, Luc Decker^{1

2}, Woottichai Khamduang², Linda Harrison¹³, Camlin Tierney¹³, John A Shepherd^{3

14}, Athena P Kourtis¹⁵, Marc Bulterys^{15

16}, George K Siberry¹⁷, Gonzague Jourdain^{1

2

5}

Affiliations

¹ Institut de Recherche pour le Développement (IRD)-PHPT, Chiang Mai University, Thailand.
² Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
³ Department of Radiology and Biomedical Imaging, University of California-San Francisco.
⁴ Department of Radiology, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Thailand.
⁵ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁶ Banglamung Hospital, Chon Buri.
⁷ Nopparat Rajathanee Hospital, Bangkok.
⁸ Samutprakarn Hospital, Samut Prakan.
⁹ Nakornping Hospital, Chiang Mai.
¹⁰ Khon Kaen Hospital, Thailand.
¹¹ Chiang Kham Hospital, Thailand.
¹² Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom.
¹³ Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
¹⁴ Population Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu.
¹⁵ Centers for Disease Control and Prevention, Atlanta, Georgia.
¹⁶ Department of HIV/Hepatitis, WHO Global Hepatitis Programme, Geneva, Switzerland.
¹⁷ Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Abstract

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

Keywords: bone mineral density; growth; hepatitis B; pregnancy; tenofovir disoproxil fumarate.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antiviral Agents / therapeutic use*
Bone Density / drug effects*
Double-Blind Method
Female
Gestational Age
Hepatitis B / drug therapy*
Hepatitis B virus
Humans
Infant
Infectious Disease Transmission, Vertical / prevention & control*
Male
Postpartum Period
Pregnancy
Pregnancy Complications, Infectious / prevention & control
Pregnancy Complications, Infectious / virology
Tenofovir / therapeutic use*
Viral Load / drug effects
Young Adult

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Associated data

Grants and funding